title: [Efficacy of unfixed continuation phase short-course chemotherapy].
abstract: OBJECTIVE
  To evaluate the efficacy of the short-course chemotherapy shorter than six months.
  
  
  METHODS
  The 2SHRZ/xHR regimen was used in 290 smear positive new untreated tuberculosis patients. The duration of continuation phase was not fixed, just in accordance with the speed of sputum negative conversion. The treatment was continued until sputum negative conversion mantained for three consecutive months.
  
  
  RESULTS
  Two hundred eighty-three out of 290 patients were cured. The sputum negative conversion rate at the end of the sixth month was 98.3%. The duration of treatment was 4.7 months on the average. The rate of two-year follow-up was 94.3%, and the rate of bacteriological relapse during two-year follow-up was 1.9%.
  
  
  CONCLUSIONS
  The results showed that the length of the six-month short-course chemotherapy could be shortened, and its recent and long-term efficacy was found satisfactory.
authors.affiliation: Beijing Tuberculosis & Thoracic Tumor Institute.
authors.forename: C
authors.initials: C
authors.lastname: Xiao
authors.forename: Y
authors.initials: Y
authors.lastname: Fu
authors.forename: Z
authors.initials: Z
authors.lastname: Li
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000008:administration & dosage; D012008:Recurrence; D012293:Rifampin / Q000008:administration & dosage; D013307:Streptomycin / Q000008:administration & dosage; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin